Remove 2021 Remove Chemotherapy Remove Compounding
article thumbnail

Innovation in chemotherapy: Leading companies in platinum-based cancer drug compositions

Pharmaceutical Technology

Platinum-based cancer drug compositions is a key innovation area in chemotherapy Platinum-based drugs are chemotherapeutic agents used for the treatment of cancer. These compounds cause their therapeutic effect by inhibiting DNA synthesis.

article thumbnail

Innovation in chemotherapy: Leading companies in purine derivatives-based cancer drug compositions

Pharmaceutical Technology

Purine derivatives-based cancer drug compositions is a key innovation area in chemotherapy Purine is an important heterocyclic nucleus in the chemical architecture of many bioactive compounds. Among its key functions, it interacts with nucleic acids and enzymes during their synthesis and function.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Targeting tumours with novel radiopharmaceuticals

European Pharmaceutical Review

With alpha particles, you must be very careful how the drug is made to ensure that the compound remains stable between manufacturing and use. How do you perceive radiopharmaceuticals complementing existing cancer treatments, such as chemotherapy and immunotherapy? What do you envision the future of radiopharmaceuticals to be like?

article thumbnail

Pfizer acquires ADC pioneer Seagen for $43bn

Pharmaceutical Technology

The drug is currently licensed in combination with chemotherapy for patients with classical Hodgkin lymphoma, both as frontline therapy and for those at risk of progressing or having progressed following stem cell transplantation. Tivdak, a tissue-factor targeting ADC that was developed in collaboration with Genmab, was approved in 2021.

article thumbnail

Eisai joins the ADC golden rush

Pharmaceutical Technology

The agent is a human epidermal growth factor receptor 2 (HER2)-targeting ADC that utilises Eisai’s chemotherapy Halaven (eribulin) as its payload. The drug became a blockbuster last year, with sales reaching $1.9bn, up from $599m in 2021. The company generated almost $2bn in revenue in 2022, a close to 25% increase from 2021.

article thumbnail

There is a large pipeline of CAR-T cell therapies for diffuse large B-cell lymphoma

Pharmaceutical Technology

billion in 2021 and is forecast to reach $2.4 By 2028, the market is expected to reach $25 billion, with a compound annual growth rate (CAGR) of 46.6%. According to GlobalData’s Epidemiology database, there were 5,446 incident cases of DLBCL in the UK in 2021. billion by the end of 2022.

article thumbnail

PROTAC development gains momentum, but clinical performance is poor

Pharmaceutical Technology

This makes early R&D less risky, as many lead compounds are discontinued due to inadequate pharmacokinetic profiles and require excessively high dosages to be pharmaceutically active. Both degraders, ARV-110 (bavdegalutamide) and ARV-766, are being developed by Arvinas.